This website uses cookies to collect necessary user browsing behaviors so that we can provide you with a better browsing experience. For more information, Please review the privacy policy

Disabling cookies will make it impossible to use member-related functions

The member-related functions have been closed due to the deactivation of cookies. Should reactivate cookies?

  • About EirGenix
    • About EirGenix
    • Vision and Mission
    • Milestones
    • Facilities and Capacities
      • Xizhi Facility
      • Zhubei Facility
    • Management Team
      • LEE-CHENG LIU
      • Klaus Martin
      • CHIH-JUNG CHANG
      • PORTIA LIN
      • HSIU-CHUAN YANG
      • SHANG-CHUNG JU
      • AE-NING LIN
      • HARK CHEN
      • Ywan-Feng Li
    • Videos
    • 360-Degree Virtual Tour
  • News
    • EirGenix Activities
    • News
    • Events
  • Services
    • Cell Line Development
    • Process Development
    • Analytical & Quality Control
    • cGMP Manufacturing - Mammalian System
    • cGMP Manufacturing - Microbial System
    • ADC & Bioconjugates
  • Products & Pipeline
    • Commercial / Market-Available Products
      • (EIRGASUN®/HERWENDA®) Trastuzumab Biosimilar
    • Pipeline — Biologic Therapeutic Candidates
    • Supporting Products & Platforms
      • HRV3C Protease
      • CRM197
  • Investor
    • Financials
      • Monthly Revenue
        • 2025
        • 2024
        • 2023
        • 2022
        • 2021
        • 2020
        • 2019
        • 2018
      • Financial Reports
        • 2024
        • 2023
        • 2022
        • 2021
        • 2020
        • 2019
        • 2018
    • Corporate Governance
      • Corporate Governance
      • Board of Directors
      • Internal Audit
    • Shareholder Services
      • Shareholders' Meeting
      • Investor Conference
      • Dividend Distribution
      • Market Observation Post System
      • Investor Relations & Media Contact
      • Stock Transfer Agent
    • ESG
      • ESG Overview
  • Recruiting
| EN | 繁中
0
Inquiry
  • EN
  • 繁中
Contact us
0
Inquiry
  • About EirGenix
    • About EirGenix
    • Vision and Mission
    • Milestones
    • Facilities and Capacities
      • Xizhi Facility
      • Zhubei Facility
    • Management Team
      • LEE-CHENG LIU
      • Klaus Martin
      • CHIH-JUNG CHANG
      • PORTIA LIN
      • HSIU-CHUAN YANG
      • SHANG-CHUNG JU
      • AE-NING LIN
      • HARK CHEN
      • Ywan-Feng Li
    • Videos
    • 360-Degree Virtual Tour
  • News
    • EirGenix Activities
    • News
    • Events
  • Services
    • Cell Line Development
    • Process Development
    • Analytical & Quality Control
    • cGMP Manufacturing - Mammalian System
    • cGMP Manufacturing - Microbial System
    • ADC & Bioconjugates
  • Products & Pipeline
    • Commercial / Market-Available Products
      • (EIRGASUN®/HERWENDA®) Trastuzumab Biosimilar
    • Pipeline — Biologic Therapeutic Candidates
    • Supporting Products & Platforms
      • HRV3C Protease
      • CRM197
  • Investor
    • Financials
      • Monthly Revenue
        • 2025
        • 2024
        • 2023
        • 2022
        • 2021
        • 2020
        • 2019
        • 2018
      • Financial Reports
        • 2024
        • 2023
        • 2022
        • 2021
        • 2020
        • 2019
        • 2018
    • Corporate Governance
      • Corporate Governance
      • Board of Directors
      • Internal Audit
    • Shareholder Services
      • Shareholders' Meeting
      • Investor Conference
      • Dividend Distribution
      • Market Observation Post System
      • Investor Relations & Media Contact
      • Stock Transfer Agent
    • ESG
      • ESG Overview
  • Recruiting
| EN | 繁中

Search

  • Home
  • Sitemap

Sitemap

  • About EirGenix
    • About EirGenix
    • Vision and Mission
    • Milestones
    • Facilities and Capacities
      • Xizhi Facility
      • Zhubei Facility
    • Management Team
      • LEE-CHENG LIU
      • Klaus Martin
      • CHIH-JUNG CHANG
      • PORTIA LIN
      • HSIU-CHUAN YANG
      • SHANG-CHUNG JU
      • AE-NING LIN
      • HARK CHEN
      • Ywan-Feng Li
    • Videos
    • 360-Degree Virtual Tour
  • News
    • EirGenix Activities
    • News
    • Events
  • Services
    • Cell Line Development
    • Process Development
    • Analytical & Quality Control
    • cGMP Manufacturing - Mammalian System
    • cGMP Manufacturing - Microbial System
    • ADC & Bioconjugates
  • Products & Pipeline
    • Commercial / Market-Available Products
      • (EIRGASUN®/HERWENDA®) Trastuzumab Biosimilar
    • Pipeline — Biologic Therapeutic Candidates
    • Supporting Products & Platforms
      • HRV3C Protease
      • CRM197
  • Investor
    • Financials
      • Monthly Revenue
        • 2025
        • 2024
        • 2023
        • 2022
        • 2021
        • 2020
        • 2019
        • 2018
      • Financial Reports
        • 2024
        • 2023
        • 2022
        • 2021
        • 2020
        • 2019
        • 2018
    • Corporate Governance
      • Corporate Governance
      • Board of Directors
      • Internal Audit
    • Shareholder Services
      • Shareholders' Meeting
      • Investor Conference
      • Dividend Distribution
      • Market Observation Post System
      • Investor Relations & Media Contact
      • Stock Transfer Agent
    • ESG
      • ESG Overview
  • Recruiting
    Contact Us

     

    Our professional team is always ready to address all your concerns.

    MORE
    TOP
    EirGenix, Inc.
    • No. 101, Lane 169, Kangning St., Xizhi Dist, New Taipei City 22180, Taiwan, R.O.C
    • +886-2-7708-0123
    EirGenix Inc. Zhubei
    • No. 168, Section 1, Shengyi Road, Zhubei City, Hsinchu County, Taiwan

    • +886-3-620-5088

    EirGenix Europe GmbH
    • c/o REGUS Business Center, Theresienhöhe
      28, 80339 München, Germany

    • +49 89 896798-100

    TOP
    • Sitemap
    • Privacy Policy
    • EIP
    • LINKEDIN
    • YOUTUBE
    copyright © 2026 EirGenix, Inc. all rights reserved.
    privacy policy site map